ASCO 2021 | Anti CD7 CAR T-cell therapy in T-ALL
Rayne Rouce
• 27 May 2021
Rayne H Rouce, MD, Baylor College of Medicine, Houston, TX & Texas Children’s Hospital, Houston, TX, summarizes the results of the Phase I trial (ChiCTR2000034762) assessing the safety and efficacy of CD7 chimeric antigen receptor (CAR) T-cell therapy in pediatric patients with T-cell acute lymphoblastic leukemia (T-ALL). The CAR T-cells were either derived from previous hematopoietic stem cell transplantation donors or haploidentical donors and in a cohort of 20 patients, 19 showed a response, demonstrating promising results in the first pediatric trial targeting CD7 in T-ALL. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
